TherapeuticsMD Inc. (NASDAQ:TXMD) went down by -3.60% from its latest closing price compared to the recent 1-year high of $2.75. The company’s stock price has collected 7.20% of gains in the last five trading sessions. Press Release reported on 05/25/21 that TherapeuticsMD Announces Submission of Low Dose BIJUVA(R) 0.5 mg/100 mg Supplemental New Drug Application to FDA
Is It Worth Investing in TherapeuticsMD Inc. (NASDAQ :TXMD) Right Now?
Plus, the 36-month beta value for TXMD is at 1.91. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for TherapeuticsMD Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $5.20. TXMD currently public float of 361.91M and currently shorts hold a 17.14% ratio of that float. Today, the average trading volume of TXMD was 8.81M shares.
TXMD’s Market Performance
TXMD stocks went up by 7.20% for the week, with a monthly jump of 28.85% and a quarterly performance of -15.72%, while its annual performance rate touched -0.74%. The volatility ratio for the week stands at 6.14% while the volatility levels for the past 30 days are set at 5.87% for TherapeuticsMD Inc.. The simple moving average for the period of the last 20 days is 12.13% for TXMD stocks with a simple moving average of -4.02% for the last 200 days.
TXMD Trading at 10.79% from the 50-Day Moving Average
After a stumble in the market that brought TXMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.27% of loss for the given period.
Volatility was left at 5.87%, however, over the last 30 days, the volatility rate increased by 6.14%, as shares surge +31.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, TXMD rose by +7.20%, which changed the moving average for the period of 200-days by -14.65% in comparison to the 20-day moving average, which settled at $1.2110. In addition, TherapeuticsMD Inc. saw 10.74% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TXMD starting from Thompson Tommy G, who purchase 5,000 shares at the price of $1.06 back on May 14. After this action, Thompson Tommy G now owns 704,600 shares of TherapeuticsMD Inc., valued at $5,300 using the latest closing price.
Donegan Michael C, the CAO and VP Finance of TherapeuticsMD Inc., sale 4,842 shares at $1.04 during a trade that took place back on May 11, which means that Donegan Michael C is holding 14,158 shares at $5,036 based on the most recent closing price.
Stock Fundamentals for TXMD
Current profitability levels for the company are sitting at:
- -239.76 for the present operating margin
- +73.77 for the gross margin
The net margin for TherapeuticsMD Inc. stands at -282.90. The total capital return value is set at -91.74, while invested capital returns managed to touch -109.45. Equity return is now at value 193.30, with -82.60 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 7.73, with the company’s debt to enterprise value settled at 0.50. The receivables turnover for the company is 2.29 and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.17.